Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021.
| Autor: | Hess LM; Eli Lilly and Company, Indianapolis, Indiana., Krein PM; LOXO Oncology, a wholly-owned subsidiary of Eli Lilly and Company, Indianapolis, Indiana., Haldane D; Eli Lilly and Company, Indianapolis, Indiana., Han Y; Eli Lilly and Company, Indianapolis, Indiana., Sireci AN; LOXO Oncology, a wholly-owned subsidiary of Eli Lilly and Company, Indianapolis, Indiana. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JTO clinical and research reports [JTO Clin Res Rep] 2022 May 07; Vol. 3 (6), pp. 100336. Date of Electronic Publication: 2022 May 07 (Print Publication: 2022). |
| DOI: | 10.1016/j.jtocrr.2022.100336 |
| Abstrakt: | Introduction: NSCLC is a solid tumor with a growing number of actionable biomarkers that may inform treatment. Current guidelines recommend a broad, panel-based approach be taken to identify actionable markers. This retrospective study used a deidentified electronic health records database in the United States to evaluate utilization of various testing modalities. Methods: Data from all adult patients diagnosed with having advanced/metastatic nonsquamous NSCLC between January 2015 and March 2021 were eligible if there was evidence of systemic therapy within 90 days of diagnosis. Results: Records from a total of 17,513 patients (91.6% from community-based practices) were eligible with 83,064 genomic biomarker tests recorded from 2015 to 2021. The proportion of patients who received biomarker testing by next-generation sequencing (NGS)-based methods ranged from 28.3% in 2015 to 68.1% in 2020. The proportion of biomarker testing methods with inconclusive or unsuccessful results ranged from 3.4% for NGS to 9.7% for fluorescence in situ hybridization. The median time to receive results ranged from 4.0 days for polymerase chain reaction-based tests to 10.0 days for immunohistochemistry- and NGS-based tests. Median time to receive results was 8 days for academic and 9 days for community practices. Conclusions: These real-world data suggest increased adoption of NGS-based testing, yet nearly one-third of all patients with advanced/metastatic nonsquamous NSCLC still did not receive broad-based genomic testing by 2020. (© 2022 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|